Skip to content

24th Annual Cancer Leadership Reception

24th Annual Cancer Leadership Reception

On September 29, 2020, the Friends of Cancer Research (Friends) 24th Annual Cancer Leadership Reception brought supporters together for a special town hall with the Nation’s top scientific leaders in the fight to treat and cure COVID-19 and cancer. Those exciting remarks and panels from experts in cancer and drug development are included below.

 

 

Dr. Francis Collins and Dr. Anthony Fauci Keynote Conversation

Dr. Francis Collins, Director of the National Institutes of Health (NIH), and Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), NIH,gave a thought provoking keynote conversation discussing the impact of the pandemic on research, how their work is evolving in 2020, and how they see the future of cancer research and drug development in the years to come.

Dr. Francis Collins and Dr. Anthony Fauci
Full Keynote Conversation

 

 

Dr. Anthony Fauci Q&A

Dr. Anthony Fauci then addressed questions from the audience, discussing the importance of the Drug and Safety Monitoring Board (DSMB), and detailing the process for vaccine approval, touting the importance of the data monitoring system and experts involved.

Dr. Anthony Fauci Full Q&A

 

 

 

Dr. Janet Woodcock, Dr. Peter Marks, and Dr. Mark McClellan

Following this discussion, Dr. Janet Woodcock, Therapeutic Lead of Operation Warp Speed at the U.S. Department of Health and Human Services, Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER), FDA, and Dr. Mark McClellan, Director of the Duke-Margolis Center for Health Policy at Duke University and Former FDA Commissioner, conducted a conversation on COVID-19 and cancer. Dr. Woodcock focused her comments on Operation Warp Speed and the importance of the clinical trial process while Dr. Marks assured attendees that any Emergency Use Authorization (EUA) granted for a vaccine would require the same level of evidence as a full approval.

Dr. Woodcock, Dr. Marks, and Dr. McClellan
Full Conversation on COVID-19 and Ca…

 

 

 

FDA Commissioner Stephen Hahn Opening Remarks

FDA Commissioner Stephen Hahn opened the event with opening remarks on the future of the agency in the world of cancer and it’s response to the pandemic.

FDA Commissioner Hahn Full Remarks

 

 

 


24th Cancer Leadership Reception Sponsors

Innovators

Pennie & Gary Abramson
The Rona and Jeffrey Abramson Foundation
Galena Yorktown Foundation
Marlene Malek
Ellen and Gerry Sigal

Champions

AstraZeneca
Kenneth Grunley
Pfizer

Collaborators

ACT for NIH
Allogene
Maddy and Jim Berlin
GRAIL
Judy and Peter Blum Kovler Foundation
Foundation Medicine
Kite Pharmaceuticals
Merck & Co.
Novartis
Pharmacyclics
Pfizer Inc
Sanofi Genzyme
Seattle Genetics

Partners

Aetion
Alexion
American Association for Cancer Research (AACR)
American Clinical Laboratory Association
Bayer Healthcare
BD
Biotechnology Innovation Organization
Deloitte
Eli Lilly and Company
EQRx
Genentech
Greenleaf Health, Inc.
Richard and Rachel Klausner
David and Nicole Mitchell
Tempus
Thrive Earlier Detection
Vertex

Supporters

BGR Group
bluebird bio
Deerfield Partners
Eisai Pharmaceuticals
Epstein Family Foundation
Flatiron Health
Incyte
The Johns Hopkins University
Tmunity
USP

Patrons

Miriam and Sanford Ain
Carolyn Aldige
Dr. Jeffrey Akman and Mr. Steven Mazzola
Margaret Anderson and Jeffrey D’Eramo
Anna Barker
Grace Bender
Dr. Philip and Faith Bobrow
Catalyst Healthcare Consulting
Joel and Barbara Finkelstein
Lucy Fisher and Doug Wick
Jack Loeb
National Pharmaceutical Council
Palo Alto Investors
Steve Pomerantz and Karen Tandy
The Sherry Lansing Foundation
James Tananbaum
Elizabeth Thompson
Robert C. Young, MD
Lynne Zydowsky